Fig. 5

ROC analysis of skeletal muscle index (SMI) predicting above-median overall survival (OS) for (a) patients with pancreatic cancer (> 19.9 months [95% CI, 16.0 to 23.0 months]), and (b) patients with metastatic colorectal cancer (> 47.9 months [95% CI, 40.7 to 61.0 months]). The red line represents SMI derived from manual psoas muscle measurements (SMpsoas) at the center of L3, while the blue line represents SMI based on total skeletal muscle tissue (SMtotal) averaged across all levels of L3 as determined by the pipeline.